Yale Cancer Center NCTN
耶鲁大学癌症中心 NCTN
基本信息
- 批准号:9236161
- 负责人:
- 金额:$ 95.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-16 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:Advanced Malignant NeoplasmAdvocateAntimetabolitesCalendarCancer BiologyCancer CenterCancer HospitalCancer PatientCaringClinicalClinical OncologyClinical ResearchClinical TrialsClinical Trials Cooperative GroupComprehensive Cancer CenterDermatologicDermatologyDisciplineDiseaseDoctor of MedicineEnsureFund RaisingFundingGeneral HospitalsGrantGynecologic OncologyHematologyHospitalsIndividualInstitutesIntentionLaboratoriesLeadLeadershipMalignant NeoplasmsMassachusettsMedical OncologyMentorsMentorshipNational Clinical Trials NetworkOperations ResearchOperative Surgical ProceduresPersonnel StaffingPharmacologyPhysiciansPositioning AttributePrincipal InvestigatorRadiation OncologyRecording of previous eventsRecruitment ActivityResearchResearch InfrastructureResearch PersonnelResourcesSiteSupervisionSurgeonSystemTimeTrainingTranslational ResearchUnited StatesUniversitiesVisionWarWorkYale Cancer Centerbasecancer pharmacologycancer research center directorcancer therapycareerdrug developmentmedical schoolsnext generationprogramspublic health relevanceresponsestandard of care
项目摘要
DESCRIPTION (provided by applicant): This application proposes that Yale University become a Network Lead Academic Participating Site (LAPS) under the newly established NCI National Clinical Trials Network. As an LAPS Yale University will 1. Promote and advocate for NCTN clinical research at the Yale Comprehensive Cancer Center (YCC); 2.continue expanding accrual to NCTN trials and provide broad based access to these important national trials to YCC membership; 3. Provide the scientific leadership necessary in order to advance the cause of NCI funded research in the NCTN system and lead important trials that will advance cancer treatment and standard of care; 4. Provide the translational science and laboratory support for these NCTN clinical trials; 5. Train and mentor Young Investigators in the NCTN groups and help them to provide the next generation of scientific leadership
描述(由申请人提供):本申请建议耶鲁大学成为新成立的 NCI 国家临床试验网络下的网络主导学术参与站点 (LAPS)。作为 LAPS 耶鲁大学将 1. 促进和倡导耶鲁综合癌症中心 (YCC) 的 NCTN 临床研究; 2. 继续扩大 NCTN 试验的收益,并为 YCC 会员提供广泛参与这些重要国家试验的机会; 3. 提供必要的科学领导,以推进 NCTN 系统中 NCI 资助的研究事业,并领导重要试验,以推进癌症治疗和护理标准; 4. 为这些NCTN临床试验提供转化科学和实验室支持; 5. 培训和指导 NCTN 小组中的青年研究者,帮助他们提供下一代科学领导力
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES S FUCHS其他文献
CHARLES S FUCHS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES S FUCHS', 18)}}的其他基金
Impact of Celecoxib and Inflammation on Survival in Stage III Colon Cancer
塞来昔布和炎症对 III 期结肠癌生存的影响
- 批准号:
8505928 - 财政年份:2013
- 资助金额:
$ 95.15万 - 项目类别:
Impact of Celecoxib and Inflammation on Survival in Stage III Colon Cancer
塞来昔布和炎症对 III 期结肠癌生存的影响
- 批准号:
8912878 - 财政年份:2013
- 资助金额:
$ 95.15万 - 项目类别:
Impact of Celecoxib and Inflammation on Survival in Stage III Colon Cancer
塞来昔布和炎症对 III 期结肠癌生存的影响
- 批准号:
9341076 - 财政年份:2013
- 资助金额:
$ 95.15万 - 项目类别:
Impact of Celecoxib and Inflammation on Survival in Stage III Colon Cancer
塞来昔布和炎症对 III 期结肠癌生存的影响
- 批准号:
8737807 - 财政年份:2013
- 资助金额:
$ 95.15万 - 项目类别:
Impact of Celecoxib and Inflammation on Survival in Stage III Colon Cancer
塞来昔布和炎症对 III 期结肠癌生存的影响
- 批准号:
9132181 - 财政年份:2013
- 资助金额:
$ 95.15万 - 项目类别:
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis
胰腺癌流行病学前瞻性队列合作
- 批准号:
8325137 - 财政年份:2008
- 资助金额:
$ 95.15万 - 项目类别:
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis
胰腺癌流行病学前瞻性队列合作
- 批准号:
7579332 - 财政年份:2008
- 资助金额:
$ 95.15万 - 项目类别:
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis
胰腺癌流行病学前瞻性队列合作
- 批准号:
8137000 - 财政年份:2008
- 资助金额:
$ 95.15万 - 项目类别:
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis
胰腺癌流行病学前瞻性队列合作
- 批准号:
7940990 - 财政年份:2008
- 资助金额:
$ 95.15万 - 项目类别:
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis
胰腺癌流行病学前瞻性队列合作
- 批准号:
7488921 - 财政年份:2008
- 资助金额:
$ 95.15万 - 项目类别:
相似海外基金
The Role of Ethnic Racial Discrimination on the Development of Anxious Hypervigilance in Latina Youth
民族种族歧视对拉丁裔青少年焦虑过度警觉的影响
- 批准号:
10752122 - 财政年份:2024
- 资助金额:
$ 95.15万 - 项目类别:
Differences in Hospital Nursing Resources among Black-Serving Hospitals as a Driver of Patient Outcomes Disparities
黑人服务医院之间医院护理资源的差异是患者结果差异的驱动因素
- 批准号:
10633905 - 财政年份:2023
- 资助金额:
$ 95.15万 - 项目类别:
2/2 IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
2/2 血管疾病的改善结果 - 主动脉夹层 (IMPROVE-AD)
- 批准号:
10663555 - 财政年份:2023
- 资助金额:
$ 95.15万 - 项目类别:
Learning and Living with Wildfire Smoke: Creating Clean Air Environments in Schools through Youth Participatory Action Research
与野火烟雾一起学习和生活:通过青年参与行动研究在学校创造清洁的空气环境
- 批准号:
10662674 - 财政年份:2023
- 资助金额:
$ 95.15万 - 项目类别:
PUFA metabolism for prevention and treatment of TMD pain: an interdisciplinary, translational approach.
PUFA 代谢预防和治疗 TMD 疼痛:一种跨学科的转化方法。
- 批准号:
10820840 - 财政年份:2023
- 资助金额:
$ 95.15万 - 项目类别: